Trial Profile
A Multi-Center, Unblinded, Single-Arm Study to Evaluate Sex Differences in the Acute Effects of PL-3994 on Myocardial cGMP Enhancement and Hemodynamics in Heart Failure With Preserved Ejection Fraction
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs PL 3994 (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- Sponsors Palatin Technologies
- 13 Dec 2021 Planned End Date changed from 30 Nov 2021 to 31 Mar 2023.
- 13 Dec 2021 Planned primary completion date changed from 31 Oct 2021 to 31 Mar 2022.
- 14 Sep 2021 Status changed from not yet recruiting to recruiting.